Cover von The future of HIV-1 therapeutics opens in new tab

The future of HIV-1 therapeutics

resistance is futile?
0 ratings
Search for this author
Year: 2015
Publisher: Cham [u.a.], Springer
Series: Current topics in microbiology and immunology; 389
Media group: Serien
available

Copies

BranchLocationsStatusReservationsDue dateBarcodeFloor planLending note
Branch: Hauptstelle Locations: Serie Status: available Reservations: 0 Due date: Barcode: 00273465 Floor plans: Floor plan Lending note:

Content

This volume thoroughly covers HIV-1 antiretrovirals currently in clinical use, together with their advantages and limitations. HIV-1 inhibitor resistance is discussed in detail, and critical assessments as to what will be required of future antiretrovirals in order to halt viral replication, reduce viral resistance, and alter the state of viral latency are presented. Experts at the forefront of HIV-1 research provide overviews of approaches from the fields of virology, chemical biology and structural biology for obtaining small molecule inhibitors that target viral regulatory and structural components at multiple points in the viral lifecycle. The individual chapters will appeal to scientists and clinicians alike.
 

Ratings

0 ratings
0 ratings
0 ratings
0 ratings
0 ratings

Details

Search for this author
Statement of Responsibility: Bruce E. Torbett ; Davis S. Goodsell ; Douglas D. Richman, editors
Year: 2015
Publisher: Cham [u.a.], Springer
opens in new tab
Classification: Search for this systematic ZB-90, MB-40
Subject type: Search for this subject type Sammelwerk
ISBN: 978-3-319-18517-0
ISBN (2nd): 3-319-18517-9
Description: X, 254 S. : Ill., graph. Darst.
Series: Current topics in microbiology and immunology; 389
Tags: Immunbiologie; Medizinische Mikrobiologie
Participating parties: Search for this character Torbett, Bruce E. [Hrsg.]; Goodsell, David S. [Hrsg.]; Richman, Douglas D. [Hrsg.]
Language: Englisch
Footnote: Literaturangaben
Media group: Serien